Pharma's year of trouble and strife

Abstract

Safety in the spotlight The year began, much as 2004 had ended, with Vioxx (rofecoxib; Merck) and the other cyclooxygenase-2 (COX2) inhibitors dominating the headlines. In February, an FDA Advisory Committee narrowly voted 17–15 in favour of the overall risk–benefit profile for Vioxx supporting marketing in the US. The committee voted 17–13 with two… (More)
DOI: 10.1038/nrd1944

Topics

  • Presentations referencing similar topics